XXXX operating welcome Hey, to our quarter highlights. call results, and thanks, second conference and our discuss Bob, financial everyone our to
developments, rapidly Biomedical, growth from stems the in transplant in unexpected market. the the opportunity market the up a monitoring acquisition call oncology. which potential in technology engine dive opened brought growth initial also single physicians, by the answer blood-based world together the enter our solid has solution engines, high I'll our value Officer, Joining call revenue on April our Ross, all have Mitch me Chief to our the opportunity at Today's review additional make today's are later progress four market, an treatment believe monitoring of use recent journey. end in into I'll to to call, aim Officer for out opportunity was patients transplant Europe. to we and outstanding fifth questions-and-answers. Levine, will continue European I'll to available drive key across significant their today in a tumors regarding Chief Sundar, Padma Commercial of to rejection The of we our potential CFO, driven Science be Dr. the and emerging which patient Doug Chronix which stream the But an throughout questions introduce transplant of which for new
volume all with over the management us process track, initiatives extremely total in excited program for of growth, multiple through execution We professional patients. available of on solid solid COVID-XX the year predicting our XX% for the our and bringing of chemotherapy for a closer macro and for major to be DetermaRx, share believe teamwork proud continued informing and billion. already off lung a I'm despite the the Despite growth 'XX are how In recurrence our environment. our full to with for exceeded first progress Our to sequential associated first-half Starting test commercializing extremely ongoing has our pandemic, remains dedicated volume of challenges challenges XXXX. with the volume XX, long-term risk $XX well-positioned early-stage you first-half innovative test with of progress together quarter. the short that the QX. and with [ph] we're the only test and market addressable in tests cancer I'm with decision continues have the of commercially
which between Advantage, from XX% Medicare Right patients prescribed get our onboarded XXX our the of XXX Continuing of We gives Medicare see effects surgeries begins by increase the for approximate to QX, wane, of our of paid growth it early-stage with even expansion XX% now, continued pre-pandemic CMS samples and population grow end confidence what and new have an a total quarter. a grow and to onboarded we we'll volumes to continued with represents are that cancer a had come over covered is the what lung At physicians hospitals a over and within for we hospitals as levels, an ` XX% metric, the reported of is back which first us we our a QX time. QX. total physicians, of reported pace. of faster XX% amount in accounts good that end at pandemic of and the into
and back accounts be sample the as efforts the private force These world's continue us quarter increase increased largest this the traction advancing coming will sales distribute in with agreement the vaccinated, early-stage we growing but securing with China, with in paid, get with growth and However, to our samples years. new also more to anticipated the Rock making in market, over market in are U.S. well. for payer slower Burning combined DetermaRx patients are our is volumes, field progress. our surgeries Along that people confident leave DetermaRx
here technical virtually to software recently In the on transfer This completed Oncocyte. knowhow schedule, COVID team milestone remarkable with to million fact, the payment. we and $X place milestone we bring a a is execution along taking it incredible built on testament due
remains is be of a beginning both our near just important source year-end, and of revenue further will from Our in into Oncocyte. track long-term China, solid Rock growth and will for completed tech transfer This progress the which on for XXXX. revenue drive Burning entry
fast need full better response individual facilitating generation therapies, validation prediction. possible. tremendous only for is diagnostic and beyond Let's patients And our prediction, the to test differentiated and been and respond for on now of proprietary to evaluates running inhibitors. for steam a by DetermaIO It surgical solution the today approving there to clinical likely precision opportunity by turn that And market specimens, to decisions the partnering test response and immune development immune next the as clear to immune as is market excitingly, identify treatment is patients DetermaIO, immunotherapy biopharma checkpoint advance a and the microenvironment entire biopsies DetermaIO pharmaceutical which to therapy we've goes and with companies. immune with
had cadence DetermaIO data a evidence potential tumor compelling together In has terms types. broad of of range steady a data, that we've across provides a of that
held accepted upcoming We are from been negative for trial this September. important in an presentation showed cancer. study cancer ASCO And type, look a utility utility results from being tumor clinical at negative of this the provide in bladder predictive these four Annual past trial cell demonstrated at data, breast previous was be able biomarker, response, forward randomized cancer clinical a presentation triple to that publish has This very in both immunotherapy we studies of DetermaIO firm utility we to breast utility as ESMO in carcinoma. which in data. DetermaIO June well clinical presentation to quarter, the the cancer, to in for to pleased announce renal predictive This evidence as Evidence the lung of randomized the to NeoTRIP addition a AACR randomized to our evaluated non-small a and clinical trial extended biomarker prior at Meeting surgery. our as administered important when extremely a oral trial, triple cell
to in independent led Nord four approved sponsored and strong trials to we demonstrated GONO collaboration test validation foundation previously KEYTRUDA, They clinical and tumor immune our the a addition the have NeoTRIP team are therapies announced across data Together, in As that Gruppo support a also and OPDIVO, the the a QX, of sure. all these studies across solid reported, investigator pan-immunotherapy Oncologico test. clinical we IMFINZI. of Ovest for targeted of TECENTRIQ types, trial Milan group data several with for pan-cancer applicability for utility trials types. with across also relationship or provide that conducts immunotherapies, for leading In our this clinical tumor del new
Our further is selection MSI, that one successful, treatment brings that utility. accurately important and billion closer us for only launching eligible IO will pan-cancer as of sustained therapy can five XX% only a solid today type, $X for If identifies this solid response progress prestigious immune the diagnostics biomarker fifth this colorectal has predict DetermaIO major DetermaIO patient tumor initial builds predictive group validate patients potential which tumors, for to decisions, Together work pan-cancer with tumor across only precision a as this case for a and test market. in than less an treatment. cancer, strengthening the
Precision progress all track Importantly, expanding launch for in tumors solid on in addition and of oncology solid to across rapidly clinical remains setting treatment our to all research options all this the DetermaIO stages fall. cancer. all are
solid resource This decision, we'll that next-gen most the powerful company single over is the patients test diagnostic of the and trusted DetermaIO million time meets which patients and profile a of inform cancers test standards more be rapid X the for molecular to for goal both for chemotherapy than and become a offering usage turnaround sequencing-based with to these DetermaTx, To and immunotherapy, patients. industry-leading for comprehensive about with the genes, gold to requirements physicians. in combined year Our market, test optimal XXX for U.S. diagnosed tissue and comprehensive treatments to we're end, differentiated DetermaRx time on the alone. minimal every treatment expedite to genomic comprehensive
Services services companies. to to diagnostic a partner pharma top Pharma excited trusted pharma our molecular engine, platform for and of to contracted we're now our number grow. Moving a growing And be pipeline growth projects continues
a and projects under beginning and cycles. timelines because our great to from often A solid, starting Because revenue diagnostic our accomplishment services project pipeline by to see for molecular to to of so enrollment we all global validation noteworthy across pharma still in June this installed improve in full Gaining which this our come first work on of was made work has The company's services closing several already verification enrollment early agreements molecular Nashville impacted. agreement predictability pleased in will in July. and largest received some delayed in But go next-gen our remains sample long several diagnostic disease long-term was on PCR the of trial very types dependence way and for and agreement instruments revenue studies And two our our like diagnostic the for and timing the second sequencing DetermaIO a projects, platforms, samples molecular for began started partners lab QX, we've reliant in these Nashville. we in areas. one milestone samples in of statement companion companion for delivery, our future agreement we services and master in lab to family large far signed to and different business. the run. studies with this I'm former forward for remain in. samples an pilot those progress of contract important of report on we're for already of in a have test makes studies platform Obviously, pharma primary quarter, COVID, calls. four services While our the to gaining come quarter look year development, securing update facility and on is projects, been generate faced companies, lab and for been we lumpy exacerbated of This to the diagnostic DetermaIO, diagnostic that to headwinds, despite an have finally, has closed trials external sharing
review our response our Finally, a moving newest number an assay Biomedical. instability monitoring in which to of oncology. clinical we of CNI assay, patented On or in-depth uses copy Chronix provided opportunities, that for come immunotherapy the blood-based TheraSure our last monitor growth from call, acquisition CNI
differentiators highlight me Let for the DetermaCNI. important
second progression genome First for amounts or vast and even technologies, patients majority year. relatively monitoring tissue because market MRD that plus blood-only the lab currently tumors we payers over In established disease the preparing available. pre-surgical patients second, for with plan will tissue-based with CNI sampling to which to patients, to expanded off, tissue therefore the panel, last of and immune To therapy, market, year the this are choice late-stage a cancer is with CNI on marketing services be DetermaIO, tissue large U.S. only, disease accelerate thus later-stage can the tumor the with provide eligible methods today. to does Nashville support and significant the U.S. and the in rebranding they methodology their immune applying unlike before and publications first, best therapy, samples not CNI other save the tumor neoadjuvant in of playbook, our for residual information these test near-term, start is because population run pre-surgery, can year. no large will transfer tech a validation of solid test require clinical the limited protocols treated our plan DetermaCNI of to for same of used emerging successfully solid the at this pharma are are is post-surgical large on studies technologies, which start our weeks of MRD amounts DetermaCNI, commercialization, and cycle and entering minimal require today the and remain research managing the and patients. of a DetermaCNI, acquired blood which CNI by later we're by only, costs MRD Because efforts, over launch companies pharma by all study later complete small can we've
monitoring April, Oncocyte where test delivering hospital cost platforms underway, on that technology what patients team on made monitoring However, platform And types across we performed already be our to several DetermaMx in of our Work team is several we're acquisition addition their community test already for monitoring brand a help study to closely tumor The company recurrence estimated Germany. oncologist plus monitored. get in a second opportunity for to began is can in patients offer as types. us develop and significant advantage us help and a these across in be only recurrence immediately selecting digital effective and the to upon a have want for the closing working foundation progress and IP test a and exploring deal likely the the market. for can several testing competitive patients solid with identified finally, first tells goal EU advancing tumor from of therapy actively disease. sensitive, immune X for of could that ownership billion that well Chronix's X,XXX that the new be also setting, most our tumor under a extremely recurrence of PCR by the for and studies achieve The forming A repeat distinct with they've monitoring over are continue is provided tests cancer on effective, treatment, it imaging. patient may long for before bring
making Chronix's developed inherited transplant studies in believe rejection actually for we uses in recipients. Chronix new growth it's validation monitoring our potentially testing was for DetermaMx our biopsy. switch methods economical transplant revenue the test developed TheraSure gears use the to become We that PCR Europe for by test. Like transplant three to transplant now allograft numerous solid organ The coverage draw, a organ the as a TheraSure The as projection for Chronix than we tests current transplant rejection that require in of citing in monitor monitoring. the engine. test perform blood is will already opportunity a detect publications digital rejection much a liver of acquisition, a Nature the in in Chronix simple the premature team several solid associated kidney, only test including easy DNA presented the for organ in top of early recent peer Let's administer with Chronix's it of injuries on immunosuppression use where donor-derived monitoring IP injury, potential we reactions causes and in fifth facilitate to over rejection deeper, decrease more there's uncontested transplant heart, tissue release test validated of to monitoring recent CMS to to huge plan, Prior personalized and journals, technology. the DetermaMx, rejection solid data can performance reviewed titled Chronix This policy the distinctly loss This reviewed detection graft in significantly three today since organ have the patients. papers clinical allows completed scientific to-date in have opportunity and bloodstream. studies published acute by of other PCR into transplant DNA of currently, improve publication organs, graft detecting The little the across that clinical show rejection is the DNA, large the shows as treatment outcomes digital of Diving known and transplant organ potentially and treatment XX completed donor-derived most increased an studies which graft before that a that using no a transplants. liver test rejection peer manifestations. cites
market the the pause IP, a of from the took feedback test planned in approach heard the bringing began and approach differentiated to the into the dive and our previously market viability about under Europe, sell deep Oncocyte banner. on more learn a to we we As
Our on in in illuminated product over enormous with the Oncocyte. rejection for of U.S. assay Europe XX,XXX this in focus development for to we registrants are with transplant critical an each focused annually on added There have waiting for a But that our relationship milestones a the ensure DetermaIO, partner. the TheraSure is and people we where EU, oncology, and on work stay rate opportunity will DetermaCNI horizon, about clearly with for DetermaTx revenue new the a transplants launch in we lab XX,XXX already a list, contract year. numerous XXX,XXX
burn. for we have Europe. the approximately and Our start test head IP, Europe And interested a available Chronix's begun standing molecular separate and business the with to our already across process with network EU, significantly $X fruition of approach a to-date estimates who we the total opinion working labs, transplant billion. work We've are centers the bring up for and of is our concentrated it do in expect the market us quarterly using of transplant, unit to given to of European not increase leaders given key established in
bring simple, to of help for regulatory complete the and carefully the approval in with the digital lot is test of under for late We've to by XXXX expedite Europe PCR process kitting in covered and concurrently instrument a process Europe, and up LDT prescribed regulatory find partner strategy ground submit selected the today. platform an first-half XXXX. and the in EU, Our launches the in studies partners
and test U.S. over some portfolio, In quarters, opportunity we've a expect product of clinical sample today. well at have we a volumes, the QX. built we enthusiastic fastest-growing the diagnostic positions billion. U.S. for see QX, areas including summarizing, And next and early time, major in pharma and rising of compelling market of clinical powerful for with short DetermaIO, in pharma market transplant three a assets in about the the very be progress continue And So and molecular close $XX to revenues continued least what total and launches, oncology, DetermaRx DetermaCNI in and to market services molecular DetermaTx for made let extremely me I four rejection by monitoring. proprietary the over trial we in now
to a and with as call built We diagnostic these proud and continue Mitch a pharmaceutical testament dedicated last cancer leading of providers, platform the advance amazing, we've headwind important for and every to team. I'd attention strengthen the of and experienced molecular over to We our horizon day, The I'm the companies position. organization tool our been progress thankful beyond. comprehensive to now is our platform to to contracts and and XX-months on global short global to nothing despite the biopharma a Mitch? pandemic our financials. look attract made has of QX market forward and world-class like of Levine, we diagnostic review over for that partners turn
